Abstract Purpose of Review As a chronic and relapsing disease, obesity impairs metabolism
and causes cardiovascular diseases. Although behavioral modification is important for the …

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

摘要背景评估在中国人群中糖代谢异常(糖尿病及糖尿病早期) 是否与肿瘤风险增加相关,
并寻找糖代谢异常人群中影响肿瘤风险的因素. 方法2011‐2012 年间, 来自中国大陆地区25 …

OBJECTIVE To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists
(RA) is associated with increased risk of thyroid cancer. RESEARCH DESIGN AND …

DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate
insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 …

Background Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has
neuroprotective effects in preclinical models of Parkinson's disease. We investigated …

In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …

Glucose metabolism is normally regulated by a feedback loop including islet β cells and
insulin-sensitive tissues, in which tissue sensitivity to insulin affects magnitude of β-cell …

Diabetes mellitus is a group of diseases defined by persistent hyperglycaemia. Type 2
diabetes, the most prevalent form, is characterised initially by impaired insulin sensitivity and …

Acute pancreatitis is one of the most frequent gastrointestinal causes of hospital admission
in the United States. Chronic pancreatitis, although lower in incidence, significantly reduces …